SLAS Recognizes Paul Hung, Ph.D. of COMBiNATi, Inc. With Innovation Award at SLAS2018
News Feb 11, 2018
SLAS recognized Paul Ju Sung Hung, PhD of COMBiNATi, Inc. this afternoon at SLAS2018 in San Diego, CA with the SLAS Innovation Award. Hung received the award as recognition of his exceptional podium presentation at the SLAS Annual Conference, Microfluidic Siphoning Array (MSA) – A Novel Scalable Digital PCR Integrated Platform. Hung accepted a $10,000 cash prize as part of one of the highest honors given at the conference.
Each year, SLAS Innovation Award finalists are identified based on their submitted abstracts which demonstrate exceedingly innovative research and discovery in life sciences and contribute to the exploration of technologies in the laboratory, exceed a benchmark or milestone in screening or the lead discovery process, or demonstrate an advanced and integrated use of mature technologies. The award finalist is then selected by a panel of judges who attend and score each podium presentation on the impact the work has on life sciences and technology, originality and creativity, quality of the science, and the oral presentation.
Ten 2018 SLAS Innovation Award finalists were selected to compete for this year’s cash prize, and Hung was announced as the winner at the closing ceremony and keynote presentation at SLAS2018 today. In addition to Hung, the other nine finalists who presented their work throughout the week at SLAS2018 are as follows:
Santiago Costantino, University of Montreal
Optical tools for single-cell manipulations and sequencing
Dennis Eastburn, PhD, Mission Bio Inc.
High-throughput single-cell DNA sequencing of AML tumors with droplet microfluidics
Olivier Frey, PhD, InSphero
Automating multi-tissue microphysiological systems using 3D microtissues
Rajarshi Guha, PhD, National Institutes of Health
Pharos – A Torch to Use in Your Journey In the Dark Genome
Shane Horman, PhD, Genomics Institute of the Novartis Research Foundation
An Ultra High-Throughput 3D Assay Platform for Evaluating T-cell-Mediated Tumor Killing
Transon V. Nguyen, Notable Labs
Combinatorial Drug Screening, High-Throughput Flow Cytometry, and Agile Integration: a Modern Platform for Personalized Treatment Discovery for Cancer Patients
Amy Rowat, BSc, MSc, PhD, University of California, Los Angeles
Label-free prediction of cancer cell invasion by single-cell physical phenotyping
Kevin Tsia, PhD, The University of Hong Kong
Ultrafast all-optical laser-scanning imaging - Enabling deep single-cell imaging and analysis
Julea Vlassakis, University of California, Berkeley/UCSF Joint Graduate Program in Bioengineering
Electrophoretic Cytometry Isolates Cytoskeleton Molecular Complexes of Single Cancer Cells
SLAS2018 showcased scientific advances and state-of-the-art applications of new technologies via 144 podium presentations, 350+ poster presentations, 300+ multinational exhibitors, 20 short courses, a menu of personalized career services and an abundance of intelligent network-building opportunities.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE